We wanted to know how frequently and to what degree HER2, ER, PR, and Ki-67 status changed after surgery (especially in the subset that received neoadjuvant therapy), and whether such changes were linked with patient age, tumor histologic grade, and treatment type. This evidence concerns the gene ERBB2 and neoplasm.